Torti, Carlo
 Distribuzione geografica
Continente #
NA - Nord America 751
EU - Europa 551
AS - Asia 203
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.508
Nazione #
US - Stati Uniti d'America 744
DE - Germania 119
SE - Svezia 117
SG - Singapore 74
CN - Cina 72
IT - Italia 69
UA - Ucraina 58
PL - Polonia 44
IE - Irlanda 41
FR - Francia 39
ID - Indonesia 26
FI - Finlandia 20
RU - Federazione Russa 16
GB - Regno Unito 12
IN - India 11
JP - Giappone 7
CA - Canada 5
BE - Belgio 4
HK - Hong Kong 4
NL - Olanda 4
VN - Vietnam 3
BR - Brasile 2
LT - Lituania 2
RO - Romania 2
TR - Turchia 2
BZ - Belize 1
CH - Svizzera 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
IR - Iran 1
LV - Lettonia 1
ME - Montenegro 1
MX - Messico 1
MY - Malesia 1
TW - Taiwan 1
Totale 1.508
Città #
Chandler 162
Houston 68
Singapore 56
Ashburn 49
Redmond 45
Kraków 42
Dublin 41
Jacksonville 32
San Mateo 31
New York 28
Jakarta 26
Cattolica 23
Boston 22
Wilmington 18
Nanjing 17
Dearborn 12
Lawrence 12
Milan 12
Princeton 12
Nanchang 11
Seattle 10
Marseille 9
Helsinki 8
Moscow 8
Norwalk 8
Redwood City 8
San Jose 8
Ann Arbor 6
Woodbridge 6
Bremen 5
Monza 5
Pune 5
Rome 5
Boardman 4
Brussels 4
Hong Kong 4
Los Angeles 4
Nürnberg 4
Rotonda 4
Tavagnacco 4
Albuquerque 3
Beijing 3
Capelle 3
Falls Church 3
Fremont 3
Hanoi 3
Jiaxing 3
Jinan 3
Ottawa 3
Paris 3
University Park 3
Washington 3
Changsha 2
Edinburgh 2
Fairfield 2
Fuzhou 2
Guangzhou 2
Lancaster 2
Las Vegas 2
London 2
Simi Valley 2
Springfield 2
Stalettì 2
Tianjin 2
Amsterdam 1
Augusta 1
Bangalore 1
Bari 1
Belize City 1
Berlin 1
Bern 1
Buffalo 1
Busto Arsizio 1
Casoria 1
Chengdu 1
Cormeilles-en-Parisis 1
Costa Mesa 1
Forest City 1
Frankfurt am Main 1
Hangzhou 1
Hebei 1
Indiana 1
Izmir 1
Katerini 1
Kemerovo 1
Kish 1
Kocaeli 1
Kuala Lumpur 1
Kunming 1
Lanzhou 1
Lonate Pozzolo 1
Mexico City 1
Mountain View 1
Mumbai 1
Munich 1
Philadelphia 1
Phoenix 1
Podgorica 1
Qingdao 1
Rende 1
Totale 934
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 210
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 132
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 87
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 82
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 73
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 71
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 69
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 67
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 64
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 61
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 60
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 60
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 56
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 52
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 49
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 49
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 38
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 37
HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir 37
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 36
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 33
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort 32
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure 29
The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy 29
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study 11
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice 9
Totale 1.533
Categoria #
all - tutte 7.281
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.281


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202075 0 0 0 0 6 15 10 0 3 3 14 24
2020/2021125 17 14 3 15 16 9 9 4 20 2 14 2
2021/2022164 6 9 1 6 7 4 11 30 7 7 36 40
2022/2023413 62 61 31 48 36 50 13 36 50 4 13 9
2023/2024219 10 54 1 15 4 39 13 11 3 4 42 23
2024/2025100 5 10 47 9 29 0 0 0 0 0 0 0
Totale 1.533